Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Equity Average (2016 - 2025)

Guided Therapeutics' Equity Average history spans 14 years, with the latest figure at -$5.6 million for Q3 2025.

  • For Q3 2025, Equity Average fell 16.56% year-over-year to -$5.6 million; the TTM value through Sep 2025 reached -$5.6 million, down 16.56%, while the annual FY2024 figure was -$4.3 million, 29.99% down from the prior year.
  • Equity Average for Q3 2025 was -$5.6 million at Guided Therapeutics, down from -$5.2 million in the prior quarter.
  • Across five years, Equity Average topped out at -$2.8 million in Q4 2022 and bottomed at -$9.4 million in Q1 2021.
  • The 5-year median for Equity Average is -$4.9 million (2024), against an average of -$5.1 million.
  • The largest annual shift saw Equity Average skyrocketed 58.05% in 2022 before it crashed 40.66% in 2024.
  • A 5-year view of Equity Average shows it stood at -$6.6 million in 2021, then surged by 58.05% to -$2.8 million in 2022, then crashed by 34.73% to -$3.7 million in 2023, then plummeted by 31.53% to -$4.9 million in 2024, then decreased by 13.92% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Equity Average are -$5.6 million (Q3 2025), -$5.2 million (Q2 2025), and -$5.0 million (Q1 2025).